SCHEMBL3902604

SCHEMBL3902604

CCCCCC(C(=O)O)C(N)OCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 3/20 0.49
SLC1A2 P43004 3/20 0.49
SLC1A1 P43005 3/20 0.49
MEN1 O00255 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
KMT2A Q03164 1/20 0.49
CETP P11597 3/20 0.46
CSNK1E P49674 1/20 0.46
CNR2 P34972 1/20 0.45
CTRC Q99895 1/20 0.44
ALDH1A1 P00352 1/20 0.42
CYP3A4 P08684 1/20 0.42
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8054965 0.99 CETP (0.48) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL6659175 0.96 SLC1A3 (0.50) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL3319284 0.96 SLC1A3 (0.50) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL6659171 0.96 SLC1A3 (0.50) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL2088395 0.83 CETP (0.46) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL2087815 0.83 CETP (0.49) MEN1KMT2ACETPCSNK1ECNR2
SCHEMBL8898336 0.83 CETP (0.49) MEN1KMT2ACETPCSNK1ECNR2
SCHEMBL2088824 0.83 CETP (0.49) MEN1KMT2ACETPCSNK1ECNR2
SCHEMBL2089840 0.83 CETP (0.49) MEN1KMT2ACETPCSNK1ECNR2
SCHEMBL2088389 0.83 CETP (0.49) MEN1KMT2ACETPCSNK1ECNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1615629-B1 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2009-03-18 EP disclosed
US-7375120-B2 Peptide deformylase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2008-05-20 US disclosed
US-7323448-B2 Antibacterial agents BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) 2008-01-29 US disclosed
EP-1615629-A4 PEPTIDE DEFORMYLASE INHIBITORS CHRISTENSEN SIEGFRIED B IV (US) 2007-02-28 EP disclosed
US-7148198-B2 Antibacterial agents BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) 2006-12-12 US disclosed
US-20060276409-A1 Antibacterial agents BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) 2006-12-07 US disclosed
US-20060229341-A1 Peptide deformylase inhibitors GLAXOSMITHKLINE LLC 2006-10-12 US disclosed
EP-1615629-A1 PEPTIDE DEFORMYLASE INHIBITORS Christensen, Siegfried B. IV (US) 2006-01-18 EP disclosed
US-20050014702-A1 Antibacterial agents BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) 2005-01-20 US disclosed
WO-2004098584-A1 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-11-18 WO disclosed
US-6787522-B2 BACTERIAL POLYPEPTIDE DEFORMYLASE (PDF) INHIBITORS, N-FORMYL HYDROXYLAMINE DERIVATIVES BRITISH BIOTECH PHARMACEUTICALS (GB) 2004-09-07 US disclosed
EP-1052984-B1 ANTIBACTERIAL AGENTS VERNALIS OXFORD LTD (GB) 2004-05-12 EP disclosed
US-20020165167-A1 Antibacterial agents BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) 2002-11-07 US disclosed
US-6423690-B1 Antibacterial agents BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) 2002-07-23 US disclosed
CN-1298299-A Antibacterial agent BRITISH BIOTECH PHARM (GB) 2001-06-06 CN disclosed
EP-1052984-A1 ANTIBACTERIAL AGENTS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 2000-11-22 EP disclosed
WO-1999039704-A1 ANTIBACTERIAL AGENTS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1999-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276409-A1 Antibacterial agents CBR3, CBR1, SIGMAR1 SLC1A3 3300/4885SLC1A2 4002/4885SLC1A1 2343/4885
US-20060229341-A1 Peptide deformylase inhibitors PDF, PEPD, DPEP1 SLC1A3 3318/4885SLC1A2 4306/4885SLC1A1 3802/4885
US-20050014702-A1 Antibacterial agents CBR3, CBR1, SIGMAR1 SLC1A3 3300/4885SLC1A2 4002/4885SLC1A1 2343/4885
US-20020165167-A1 Antibacterial agents CBR1, CBR3, SIGMAR1 SLC1A3 3707/4885SLC1A2 3874/4885SLC1A1 2748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.